2003
DOI: 10.1007/s005350300043
|View full text |Cite
|
Sign up to set email alerts
|

Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus

Abstract: The degree of escape by the mutant envelope protein differed according to antibody type. Of the three types of antibody used in this study, HBV immunoglobulin was least affected by mutation in the a-loop. There appears to be no correlation between antigenicity and immunogenicity of the escape mutant, and the a-loop mutant may cause hepatitis with the usual serum viral markers.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2005
2005
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(18 citation statements)
references
References 29 publications
0
18
0
Order By: Relevance
“…33 It is unclear whether the HBV vaccine became inactive in subjects during the entrant birth years of 1990 and 1991, or if the HBV pre-S1 and pre-S2 protein mutated under high pressure of nationwide implementation of the HB vaccine. [34][35][36][37] Perhaps this reflects the need for high vaccine exposure or improved dosages. The pre-S1 and pre-S2 domains of HBsAg are functional proteins of HBV for binding hepatocyte receptors, 26,[38][39][40][41][42] and the antibodies against pre-S1 domain are capable of blocking the invasion of HBV into hepatocytic cells.…”
Section: Discussionmentioning
confidence: 96%
“…33 It is unclear whether the HBV vaccine became inactive in subjects during the entrant birth years of 1990 and 1991, or if the HBV pre-S1 and pre-S2 protein mutated under high pressure of nationwide implementation of the HB vaccine. [34][35][36][37] Perhaps this reflects the need for high vaccine exposure or improved dosages. The pre-S1 and pre-S2 domains of HBsAg are functional proteins of HBV for binding hepatocyte receptors, 26,[38][39][40][41][42] and the antibodies against pre-S1 domain are capable of blocking the invasion of HBV into hepatocytic cells.…”
Section: Discussionmentioning
confidence: 96%
“…This could result in an inability to synthesize hepatitis B e antigen (HBeAg) [Marrone et al, 2003;Tacke et al, 2004] and increase the risk of hepatocellular carcinoma in hepatitis B carriers [Kao et al, 2003]. The mutations in 'a' determinant epitope of HBsAg may result in a vaccine escape mutation [Shizuma et al, 2003]. Others mutations in the pre-S region may affect secretion of virions and assembly [Luo, 2001;Kajiya et al, 2002;Kreutz, 2002].…”
Section: Introductionmentioning
confidence: 99%
“…Mutant HBV strains displaying amino-acid substitutions in the region known as the 'a' determinant of HBsAg can modify the antigenicity of the protein and may impair virion secretion and HBsAg formation [Chen et al, 2003;Shizuma et al, 2003;Khan et al, 2004], as well as the detection of the antigen by the routine diagnostic tests (Table I) [Wallace et al, 1994;Carman, 1997;Carman et al, 1997;Ireland et al, 2000;Hou et al, 2001;Allain, 2004]. Such mutants have also been reported in association with escape from vaccineinduced immunity [Oon et al, 1995;Carman, 1997;Ho et al, 1998;Chong-Jin et al, 1999;He et al, 2001;Lee et al, 2001;Seddigh-Tonekaboni et al, 2001] and with failures of therapy with specific immunoglobulin in newborns from carrier women and in liver-transplant recipients [Harrison et al, 1994;Oon et al, 1996Oon et al, , 2002Brind et al, 1997;Carman, 1997;Ngui et al, 1997;Protzer-Knolle et al, 1998;Santantonio et al, 1999;Roznovsky et al, 2000;Liu et al, 2002].…”
Section: Introductionmentioning
confidence: 99%